
Estimate Adjusted EBIT Margin

	Fiscal Year Ending					LTM
	Dec-20	Dec-21	Dec-22	Dec-23	Dec-24	Mar-25
(EUR in millions)	FY-4	FY-3	FY-2	FY-1	FY	LTM

Revenue	808	960	1,041	1,151	1,195	1,199

Adjusted EBITDA Build-up
EBT, Incl. Unusual Items	125	293	216	106	172	158
(+) Net Interest Expense	9	5	12	52	44	53
(+) Other Non Operating Exp.	3	(2)	14	26	(2)	1
(+) D&A	15	16	20	27	29	29
(+) Non-recurring Items	3	(0)	40	9	8	8
Adjusted EBITDA	155	312	302	220	251	248

(-) D&A	(15)	(16)	(20)	(27)	(29)	(29)

Adjusted EBIT	140	296	283	193	222	219
% of Revenue	17.3%	30.8%	27.2%	16.8%	18.6%	18.3%


	Low	Median	High

Adjusted EBIT Margin	16.8%	18.6%	30.8%

支持的计算方式

Equity Waterfall


Equity Waterfall

	Model
(EUR in millions)	Low	Mid	High	Market
Enterprise Value	1,622	2,112	3,986	2,704
(+) Cash & Short Term Investments	115	115	115	115
(+) Investments & Other	21	21	21	21
(-) Debt	(995)	(995)	(995)	(995)
(-) Other Liabilities	(4)	(4)	(4)	(4)
(-) Preferred Stock	0	0	0	0
(-) Other	0	0	0	0
Value of Common Equity	760	1,249	3,123	1,841
(/) Shares Outstanding	53.8	53.8	53.8	53.8
Implied Stock Price (EUR)	14.11	23.20	58.01	34.20
FX Rate: EUR/EUR	1.00	1.00	1.00	1.00
Implied Stock Price (EUR)	14.11	23.20	58.01	34.20

Upside / (Downside)	-58.74%	-32.15%	69.61%


Stock Price	34.20
Stock Price Close	34.20
Restatment Type	Original
Reporting Currency	EUR
Trading Currency	EUR
FX Rate: EUR/EUR	1.00
Market Cap	1,887.1
Shares Outstanding	53.8
Share Exchange Ratio	1.0
Liquid Long-term Investments	0

加载出错

Dermapharm Holding SE